These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 34432309)

  • 1. Skin advanced glycation end products as a diagnostic and monitoring tool among psoriatic patients: how the therapy helps reduce cardiovascular disease risk.
    Lanna C; Zangrilli A; Bavetta M; Diluvio L; Campione E; Bianchi L
    Int J Dermatol; 2022 May; 61(5):577-581. PubMed ID: 34432309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study.
    Esposito M; Giunta A; Mazzotta A; Zangrilli A; Babino G; Bavetta M; Perricone R; Chimenti S; Chimenti MS
    Dermatology; 2012; 225(4):312-9. PubMed ID: 23295383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Skin Autofluorescence, as a Measure of AGE Accumulation in Individuals Suffering from Chronic Plaque Psoriasis.
    Kopeć-Pyciarz K; Makulska I; Zwolińska D; Łaczmański Ł; Baran W
    Mediators Inflamm; 2018; 2018():4016939. PubMed ID: 30363704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-TNF-α therapy improves insulin sensitivity in non-diabetic patients with psoriasis: a 6-month prospective study.
    Pina T; Armesto S; Lopez-Mejias R; Genre F; Ubilla B; Gonzalez-Lopez MA; Gonzalez-Vela MC; Corrales A; Blanco R; Garcia-Unzueta MT; Hernandez JL; Llorca J; Gonzalez-Gay MA
    J Eur Acad Dermatol Venereol; 2015 Jul; 29(7):1325-30. PubMed ID: 25353352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship of leptin with adiposity and inflammation and resistin with disease severity in psoriatic patients undergoing anti-TNF-alpha therapy.
    Pina T; Genre F; Lopez-Mejias R; Armesto S; Ubilla B; Mijares V; Dierssen-Sotos T; Gonzalez-Lopez MA; Gonzalez-Vela MC; Blanco R; Hernández JL; Llorca J; Gonzalez-Gay MA
    J Eur Acad Dermatol Venereol; 2015 Oct; 29(10):1995-2001. PubMed ID: 25823684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics.
    Papoutsaki M; Chimenti MS; Costanzo A; Talamonti M; Zangrilli A; Giunta A; Bianchi L; Chimenti S
    J Am Acad Dermatol; 2007 Aug; 57(2):269-75. PubMed ID: 17574299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psoriasis Area and Severity Index response in moderate-severe psoriatic patients switched to adalimumab: results from the OPPSA study.
    Talamonti M; Galluzzo M; Bernardini N; Caldarola G; Persechino S; Cantoresi F; Egan CG; Potenza C; Peris K; Bianchi L
    J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1737-1744. PubMed ID: 29776016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TNF-α in a molecularly targeted therapy of psoriasis and psoriatic arthritis.
    Wcisło-Dziadecka D; Zbiciak-Nylec M; Brzezińska-Wcisło L; Mazurek U
    Postgrad Med J; 2016 Mar; 92(1085):172-8. PubMed ID: 26719452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of adalimumab in difficult-to-treat psoriasis.
    Lanna C; Zangrilli A; Bavetta M; Campione E; Bianchi L
    Dermatol Ther; 2020 May; 33(3):e13374. PubMed ID: 32246516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term treatment of psoriatic patients with adalimumab reduces disease severity and maintains a favorable lipid pattern and a low Atherogenic Index.
    Zangrilli A; Bavetta M; Scaramella M; Bianchi L
    G Ital Dermatol Venereol; 2018 Apr; 153(2):146-154. PubMed ID: 29564871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of adalimumab in the treatment of psoriasis: a retrospective study of 15 patients in daily practice.
    Sola-Ortigosa J; Sánchez-Regaña M; Umbert-Millet P
    J Dermatolog Treat; 2012 Jun; 23(3):203-7. PubMed ID: 21787203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advanced Glycation End Products in the Pathogenesis of Psoriasis.
    Papagrigoraki A; Maurelli M; Del Giglio M; Gisondi P; Girolomoni G
    Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29156622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bimekizumab versus Adalimumab in Plaque Psoriasis.
    Warren RB; Blauvelt A; Bagel J; Papp KA; Yamauchi P; Armstrong A; Langley RG; Vanvoorden V; De Cuyper D; Cioffi C; Peterson L; Cross N; Reich K
    N Engl J Med; 2021 Jul; 385(2):130-141. PubMed ID: 33891379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy comparison of ustekinumab between anti-tumor necrosis factor-α drug-naïve and anti-tumor necrosis factor-α drug-resistant Japanese psoriasis cases.
    Takahashi N; Noda S; Taniguchi T; Adachi M
    Int J Dermatol; 2015 Oct; 54(10):1194-8. PubMed ID: 26016819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adalimumab: A Review in Chronic Plaque Psoriasis.
    Burness CB; McKeage K
    Drugs; 2015 Dec; 75(18):2119-30. PubMed ID: 26586242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adalimumab for treatment of moderate to severe psoriasis and psoriatic arthritis.
    Bongiorno MR; Pistone G; Doukaki S; Aricò M
    Dermatol Ther; 2008 Oct; 21 Suppl 2():S15-20. PubMed ID: 18837728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of skin Th17 transcriptional profiles in psoriatic patients under adalimumab biotherapy.
    Buffiere-Morgado A; Couderc E; Delwail A; Favot L; Jegou JF; Solau E; Guillet G; Lecron JC; Morel F
    Eur J Dermatol; 2017 Dec; 27(6):579-589. PubMed ID: 29171393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.
    Mazzotta A; Esposito M; Costanzo A; Chimenti S
    Am J Clin Dermatol; 2009; 10(5):319-24. PubMed ID: 19658444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AURIEL-PsO: a randomized, double-blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB11022 to reference adalimumab in patients with moderate-to-severe chronic plaque-type psoriasis.
    Hercogová J; Papp KA; Chyrok V; Ullmann M; Vlachos P; Edwards CJ
    Br J Dermatol; 2020 Feb; 182(2):316-326. PubMed ID: 31206593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of psoriatic arthritis on the efficacy of adalimumab and on the treatment response of other markers of psoriasis burden: subanalysis of the BELIEVE study.
    Paul C; van de Kerkhof P; Puig L; Unnebrink K; Goldblum O; Thaçi D
    Eur J Dermatol; 2012; 22(6):762-9. PubMed ID: 23178916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.